Aura Biosciences Posts Q2 Cash Surge
Aura Biosciences ( NASDAQ:AURA ) , a biotechnology company focused on developing virus-like drug conjugates for cancer with an emphasis on ocular oncology, reported its second quarter 2025 financial results on August 13, 2025.
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights
Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer ...
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space ( SCS® ) Delivery Platform and Promising Ophthalmology Pipeline
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases ...
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space ( SCS® ) Delivery Platform and Promising Ophthalmology Pipeline - Clearside Biomedical ( NASDAQ:CLSD )
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD -
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting - Clearside Biomedical ( NASDAQ:CLSD )
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase Inhibitor - ALPHARETTA, Ga., June 17, 2025 ( GLOBE NEWSWIRE ) -- Clearside Biomedical, Inc.
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants - Aura Biosciences ( NASDAQ:AURA )
BOSTON, May 15, 2025 ( GLOBE NEWSWIRE ) -- Aura Biosciences, Inc. ( "Aura" ) AURA, a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of ( i ) ...
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants
BOSTON, May 15, 2025 ( GLOBE NEWSWIRE ) -- Aura Biosciences, Inc. ( "Aura" ) ( Nasdaq: AURA ) , a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of ...
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights
First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer ( NMIBC ). Initial Data at 3 Months Expected by ...
Why United Airlines Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Aardvark Therapeutics ( NASDAQ:AARD ) , ASML Holding ( NASDAQ:ASML )
Shares of United Airlines Holdings, Inc. UAL rose sharply in today's pre-market trading following first-quarter results. The company reported adjusted first-quarter earnings of 91 cents per share, beating estimates of 76 cents per share, according to Benzinga Pro.
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
BOSTON, April 02, 2025 ( GLOBE NEWSWIRE ) -- Aura Biosciences, Inc. ( NASDAQ: AURA ) , a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology ...
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors - Aura Biosciences ( NASDAQ:AURA )
BOSTON, April 02, 2025 ( GLOBE NEWSWIRE ) -- Aura Biosciences, Inc. AURA, a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit ...
US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert
U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading.
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress
Aura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress ...
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress - Aura Biosciences ( NASDAQ:AURA )
Aura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress Aura will Host a Virtual Urologic Oncology Investor Event Featuring Key Opinion Leaders at 4:30 pm Eastern Time on March 24, 2025 BOSTON, March 03, 2025 ( GLOBE NEWSWIRE ) -- Aura Biosciences, ...
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Aura Biosciences, Inc. ( NASDAQ: AURA ) , a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will ...
Aura Biosciences to Participate in Upcoming Investor Conferences - Aura Biosciences ( NASDAQ:AURA )
BOSTON, Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Aura Biosciences, Inc. AURA, a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the ...
Why Check-Cap Shares Are Trading Higher By Over 52%; Here Are 20 Stocks Moving Premarket - Ark Restaurants ( NASDAQ:ARKR ) , Aura Biosciences ( NASDAQ:AURA )
Shares of Check-Cap Ltd CHEK rose sharply in today's pre-market trading after the company announced it was granted European Patent Number EP4087488 titled "RADIATION CAPSULE FOR BOWEL DISEASE IMAGING AND LOCALIZE DRUG DELIVERY". Check-Cap shares jumped 52.2% to $1.75 in the pre-market trading ...
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference - Aura Biosciences ( NASDAQ:AURA )
BOSTON, Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- Aura Biosciences, Inc.
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China ...
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease - Aura Biosciences ( NASDAQ:AURA )
On Thursday, Aura Biosciences, Inc. AURA revealed early data from an ongoing Phase 1 trial of bel-sar ( AU-011 ) in patients with non-muscle-invasive bladder cancer ( NMIBC ) .
3 Small-Cap Stocks Ready to Deliver Significant Growth - Aura Biosciences ( NASDAQ:AURA ) , Franklin BSP Realty Trust ( NYSE:FBRT )
Small-cap stocks faced a challenging environment for the last several years as inflation and high interest rates dampened lending opportunities. These companies-which are often in the early stages of development and lack stability-rely heavily on debt to fuel their growth.
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study
AURA stock up as lead candidate shows tumor control and visual acuity preservation abilities in eye cancer patients over 12 months of treatment.
Aura Biosciences Touts Promising Data From Eye Cancer Candidate - Aura Biosciences ( NASDAQ:AURA )
Thursday, Aura Biosciences, Inc. AURA revealed Phase 2 end-of-study results evaluating bel-sar ( AU-011 ) for the first-line treatment of early-stage choroidal melanoma ( CM ) , a vision and ocular cancer.
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile ...
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma - Aura Biosciences ( NASDAQ:AURA )
Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders Today at 8:00 am ET BOSTON, Sept. 12, 2024 ( GLOBE NEWSWIRE ) -- Aura Biosciences, Inc.
Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer ( NMIBC ) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024
Sabine Doris Brookman-May, MD, PhD to join Aura as Senior Vice President, Clinical Development Urologic Oncology Sabine Doris Brookman-May, MD, PhD to join Aura as Senior Vice President, Clinical Development Urologic Oncology ...
Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting
Aura will Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders at 8:00 am Eastern Time on September 12, 2024 Aura will Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders at 8:00 am Eastern Time on September ...
UnitedHealth ( UNH ) , Amedisys Clear Merger Hurdle With Asset Sale
By selling these assets, UnitedHealth (UNH) and Amedisys aim to avoid potential monopoly issues and ensure a smoother merger process.
Teladoc ( TDOC ) Harnesses AI for Diabetes Care, Stock Rises 6.7%
AI can help Teladoc (TDOC) to streamline healthcare delivery, making it more efficient and scalable.
Brookdale ( BKD ) Sees 31 Months of Y/Y Occupancy Growth Streak
Brookdale's (BKD) weighted average occupancy for the second quarter-to-date rises 160 bps year over year to 78%.
Wall Street Analysts See a 162.63% Upside in Aura Biosciences ( AURA ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Aura Biosciences (AURA) points to a 162.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think Aura Biosciences, Inc. ( AURA ) Could Surge 174.29%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 174.3% in Aura Biosciences, Inc. (AURA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Wall Street Analysts Believe Aura Biosciences, Inc. ( AURA ) Could Rally 200.75%: Here's is How to Trade
The consensus price target hints at a 200.8% upside potential for Aura Biosciences, Inc. (AURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying - Aura Biosciences ( NASDAQ:AURA ) , Energy Transfer ( NYSE:ET )
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Clearside Biomedical's Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting - Clearside Biomedical ( NASDAQ:CLSD )
ALPHARETTA, Ga., Nov. 07, 2023 ( GLOBE NEWSWIRE ) -- Clearside Biomedical, Inc.
Clearside Biomedical's Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting
Robust Safety Profile and Encouraging Efficacy Data Utilizing SCS Microinjector® Featured in Multiple Data Presentations Robust Safety Profile and Encouraging Efficacy Data Utilizing SCS Microinjector® Featured in Multiple Data Presentations ...
Why Aura Biosciences Stock Hit A New 52-Week Low Today - Aura Biosciences ( NASDAQ:AURA )
Aura Biosciences Inc AURA shares are trading lower by 34.7% to $7.18 Tuesday afternoon after the company announced pricing of its public offering of common stock. Aura is conducting a public offering of 11 million common shares at $9.00 per share.
Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket - Color Star Tech ( NASDAQ:ADD ) , Alto Ingredients ( NASDAQ:ALTO )
Senti Biosciences, Inc. SNTI shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China. Tharimmune, Inc.
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Adtran ( NASDAQ:ADTN ) , Alpine Immune Sciences ( NASDAQ:ALPN )
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today's pre-market trading session. Ventyx Biosciences, Inc.
Top 5 Health Care Stocks That May Fall Off A Cliff This Month - CVRx ( NASDAQ:CVRX ) , Aura Biosciences ( NASDAQ:AURA )
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028 | DelveInsight
The medical second opinion market is expanding rapidly due to the increasing frequency of malignancies, infectious diseases, genetic diseases, cardiovascular diseases, hematological diseases, orthopedic diseases, and other diseases around the world.
Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Clearside Biomedical ( NASDAQ:CLSD )
- Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open - - Proprietary Suprachoroidal Injection Platform Featured in Peer-Reviewed Publication and at ARVO, ASRS and OIS Scientific Meetings - - Management to Host Webcast and Conference Call Today at ...
Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed, Bristol-Myers Squibb, CG Oncology, Merck, Eli Lilly and Company, UroGen, Ferring
Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed ... PR ...
Melanoma Market to Witness Promising Growth, Predicts DelveInsight | Key Companies To Watch - IO Biotech, Merck, Eisai, Regeneron, Genentech, Seagen, Amgen, Astellas, Galectin, MedImmune, Aivita, Linnaeus, Checkmate, OnKure
Melanoma Market to Witness Promising Growth, Predicts ... PR ...
Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings
- CLS-AX OASIS Results Show Favorable Safety Data, Durability and Biologic Effect Over 6 Months in ...
Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings - Clearside Biomedical ( NASDAQ:CLSD )
- CLS-AX OASIS Results Show Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - SCS Microinjector® Featured in Favorable Data Presentations Related to Multiple Therapies in Clinical Development -
Aura Biosciences Releases Data Presentation Of Eye Cancer Candidate - Aura Biosciences ( NASDAQ:AURA )
Aura Biosciences Inc AURA announced the presentation of interim Phase 2 safety and efficacy data of belzupacap sarotalocan ( bel-sar; AU-011 ) with 9-10 months of follow-up.
Why Shares of Aura Biosciences Jumped This Week
The clinical-stage biotech may be ready to release updated phase 3 trial results on its lead therapy.
$49.5 Million Bet On Howard Hughes? Check Out These 4 Stocks Insiders Are Buying - Ball ( NYSE:BALL ) , Aura Biosciences ( NASDAQ:AURA )
Although US stocks closed mostly lower on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical's Proprietary Suprachoroidal Space Platform
- Favorable Safety Profiles and Encouraging Efficacy Data Reported in Clinical Trials in the Suprachoroidal Space ( SCS® ) Across Multiple Therapeutic Areas using ...
